Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with BRAF V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to BRAF/MEK inhibition
Patients with advanced NSCLC and <i>BRAF</i> mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.
Authors
- Rong Zhou (ORCID: https://orcid.org/0000-0002-7740-5378)
- Chunlai Feng (ORCID: https://orcid.org/0000-0002-9628-1331)
- Wei Zhao
Institutions
- Soochow University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fonc.2026.1720971
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00